iBio (NYSE AMERICAN:IBIO) appointed Thomas Isett as a director, effective immediately.
Mr. Isett has decades of successful management and corporate development experience in life sciences, with notable focus on biologics contract development and manufacturing organizations (CDMOs).
In 2015, he founded i.e. Advising, a management and strategy consulting firm, as well as Commence Bio, a private, early-stage developer of cellular immunotherapies.
As managing director of i.e. Advising – and in his earlier corporate development roles – Mr. Isett advised Fortune 500 companies, private equity firms, biotechs, and standards-setting organizations on key strategy, M&A, and intellectual property decisions in life sciences. He has been involved in transactions valued at more than $20-billion.
Prior to founding i.e. Advising, Mr. Isett held leadership roles for bioprocess product and service businesses during his 25 combined years with GE, Lonza, and Becton Dickinson.
In a statement, Robert Kay, iBio chairman and CEO, said Mr. Isett’s guidance and insight would be important as iBio seeks to establish itself as a global leader in the development and manufacture of biological medicines. “Key to realizing this goal is the continued expansion of our CDMO technologies and capabilities,” he added.
Mr. Isett said iBio’s plant-based technology platform allows for rapid process development, dependable scale-up, and truly ‘green,’ sustainable bioprocessing, compared with traditional approaches.
“With these advantages and the company’s impressive, large-scale manufacturing capabilities, I believe iBio is exceptionally well positioned to meet the industry’s demands for faster, lower-cost, and more environmentally friendly production of biological medicines,” he added.